New medicine, developed by Uzbek scientists, is used to treat coronavirus

The drug "Rutan tablets 100 mg" developed by scientists of the Institute of Bioorganic Chemistry of the Academy of Sciences of the Republic of Uzbekistan was included in the protocol for the treatment of COVID-19 coronavirus infection.

According to the report, the Ministry of Health has now decided to prescribe “Rutan” to patients with coronavirus at the first sign of weakness associated with acute respiratory infections. “Rutan” is a medicine isolated from the plant Rhus coriaria (Totum), and clinical trials have indicated its effectiveness against various strains of influenza virus, as well as SARS-Cov-2 virus.

The research was conducted by the Virology Research Institute under the Ministry of Health with a grant from the Ministry of Innovation Development.

Clinical trials have depicted that the optimal dose of 100 milligrams of “Rutan” can be safely used in patients over 6 years of age, and that taking it twice a day can prevent the virus from multiplying, preventing colds and inflammation, especially acute and atypical pneumonia. It is noteworthy that the two main conservative enzymes involved in the formation of all functional and structural proteins of the virus - 3SL protease and RNA-binding RNA polymerase - have the property of inhibiting (stopping) and are plant-derived drugs. As a result, the body does not produce structural and functional proteins, and immature viruses are formed that are not capable of infection.

The advantage of “Rutan” is that it has a very low toxicity compared to other antiviral drugs, high therapeutic efficacy and no side effects.

The use of “Rutan tablets 100 mg” resulted in a significant decrease in S-reactive protein, the main mediator of inflammatory processes in COVID-19, and no patients in the treatment group developed a critical condition requiring oxygenation.

Studies have delineated that the medicine can be widely used in patients with moderate coronavirus infection.